Nicolás Federico: Aldosterone Dysregulation as a Driver of Cardiorenal Disease
Nicolás Federico, Fellow of the International Society of Hypertension, Adjunct Professor of Medicine at the National University of Cuyo, and Head of the Hypertension Unit at Hospital Español de Mendoza, shared a post on LinkedIn։
՛՛Aldosterone dysregulation as a driver of cardiorenal disease
A recent narrative review published in Current Heart Failure Reports (Erzeel et al., 2026) revisits the evolution of mineralocorticoid pathway modulation across heart failure and chronic kidney disease, shifting the focus from drugs to pathophysiology.
Rather than viewing aldosterone merely as a volume-regulating hormone, growing evidence supports its role in a broader maladaptive phenotype characterized by:
- sodium retention and volume expansion
- vascular inflammation and fibrosis
- cardiac remodeling and hypertrophy
- renal injury and albuminuria
- sympathetic overactivation
From a mechanistic perspective, different therapeutic strategies act at distinct levels of the aldosterone pathway:
Mineralocorticoid receptor antagonists (steroidal and non-steroidal) primarily block downstream tissue effects.
Emerging aldosterone synthase inhibitors aim to suppress upstream aldosterone production, potentially preventing hormonal breakthrough.
This framework highlights an important concept:
aldosterone dysregulation may define different cardiorenal phenotypes, each requiring a tailored therapeutic approach.
Importantly, this pathophysiological view may also help interpret heterogeneity in treatment response across hypertension, heart failure, and chronic kidney disease populations.
As outcome trials continue to mature, understanding where and how we intervene along this pathway will be central to precision cardiorenal medicine.՛՛
Stay updated with Hemostasis Today.
-
Jul 14, 2026, 19:35Daratumumab in Difficult-to-Treat iTTP: Updated Results from the International DarTTP Study
-
Jul 14, 2026, 17:1610 Posts Not To Miss from ISTH 2026, Part 3
-
Jul 14, 2026, 15:27Dianne E Van Der Wal: Celebrating Scientific Contributions at ISTH 2026
-
Jul 14, 2026, 15:13Alfonso Tafur: RIETE Registry Analysis Supports More Equitable Approaches to VTE Care
-
Jul 14, 2026, 15:03Heghine Khachatryan: Phase III Trial Results Support BAFF-R Inhibition in Corticosteroid-Refractory ITP
-
Jul 14, 2026, 14:51Nathan Connell: ISTH 2026 Highlights the Power of Lifelong Collaboration
-
Jul 14, 2026, 14:42Wolfgang Miesbach: VOYAGER1 Highlights Progress Toward Injection-Free Care in Hemophilia A
-
Jul 14, 2026, 12:08Elvira Grandone: Finding the Right LMWH Dose for Pregnant Patients Suffering From DVT
-
Jul 14, 2026, 12:05Eloïse Laouenan: From Washington to Paris – Join GETBO at ISTH 2026